HLA-DR molecules are heterodimeric transmembrane glycoproteins that associate intracellulMry with a polypeptide known as the invariant (I) chain. Shortly before expression of the HLA-DR ap dimer on the cell surface, however, the I chain is removed from the intracellular a(3I complex by a mechanism thought to involve proteolysis. In this report, we show that treatment of purified afiI with the cysteine prqteinase cathepsin B results in the specific proteolysis of the HLA-DR-associated I chain in vitro. As a consequence of this, the I chain is removed and free ap dimers are released from afpI. Although afI fails to bind an immunogenic peptide, the released ap3 dimers acquire the ability to bind the peptide after proteolysis of the I chain. These results suggest that the I chain inhibits inmunogenic peptide binding to afJI early during intracellular transport and demonstrate that proteolysis is likely to be the in vivo mechanism of I chain removal.
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Major histocompatibility complex (MHC) molecules are polymorphic heterodimeric glycoproteins that function by presenting immunogenic peptides to MHC-restricted T cells. Recent evidence suggests that newly synthesized class I MHC molecules bind immunogenic peptides very early in transport, perhaps as early as the endoplasmic reticulum (1) . Binding ofpeptides to class II MHC molecules is also thought to occur intracellularly; however, in this case the peptides are generated after endocytosis and proteolytic degradation of foreign antigens (2, 3) .
The human class II molecule that has been most intensively investigated is HLA-DR (DR). Immediately after synthesis, the DR af3 heterodimer associates with a nonpolymorphic polypeptide termed the invariant (I) chain (for review, see ref. 4 ). The a3-invariant chain (a,81) complex is then transported through the Golgi apparatus and, at least in human B-lymphoblastoid cell lines, the complex is delayed in a post-Golgi compartment for 2-4 hr. The DR-associated I chain is then removed from af3I and soon thereafter the ac dimer is expressed on the cell surface (5) .
Biochemical and electron microscopic evidence. suggests that after transport through the Golgi apparatus, a,11 enters a proteinase-containing compartment also intersected by the endocytic pathway (6) (7) (8) . Consistent with these findings are the results of pulse-chase analyses of class II molecules isolated from B-lymphoblastoid cells grown in the presence of the proteinase inhibitors chloroquine, leupeptin, antipain, and L-trans-epoxysuccinylleucylamido(4-guanidino)butane (E-64) (refs. 9-11 ; unpublished data). These reagents inhibit I chain proteolysis and/or dissociation from ar11 in vivo, suggesting that it is the action of endosomal proteinases that leads to the liberation of the I chain from intracellular aBl.
We have proposed that the compartment in which foreign antigen-derived peptides are generated and the compartment in which the class II-associated I chain is degraded is the same and that it is only after proteolysis ofthe I chain that the newly liberated class II acB dimer is capable of binding an immunogenic peptide (4, 10) . In support of this hypothesis are recent in vitro data that demonstrated that whereas all dimers could bind an immunogenic peptide with high affinity, a.I complexes could not bind this peptide unless the I chain was dissociated from the complex with SDS (12, 13 Proc. NatL. Acad. Sci. USA 88 (1991) 3151 preparation (25,000 cpm/pmol of *HAp) and the amount of the a,3 dimer present in the sample was determined by the methods described below. HPLC and Electrophoresis. HPLC was performed using a TSK-G3000 SW size-exclusion chromatography column (7.5 x 600 mm; Pharmacia-LKB) equilibrated in 50 mM sodium phosphate/1% n-octyl ,-D-glucopyranoside, pH 7.0 (12, 13) .
Fractions of 0.5 ml were collected at a flow rate of 0.5 ml/min. The amount of protein present in the a,8I preparations was estimated by HPLC by comparing the peak area of a sample of the aI preparation (monitored at 214 nm) to the peak area of a sample containing a known amount of ovalbumin. The amount of DR released from ac1 was estimated as a percentage of the total P chains present in the sample by immunoblot analysis of HPLC fractions with the class II ,8-chain-specific monoclonal antibody XD5.A11 (13) .
One-dimensional reducing SDS/PAGE and two-dimensional (2D) PAGE (nonequilibrium pH-gradient electrophoresis followed by reducing SDS/PAGE) were performed as described (14) . The molecular weight of unknown proteins was determined based on a standard curve obtained using 14C-labeled molecular weight standards (Amersham). HPLC fractions and all samples for 2D PAGE were precipitated with ethanol at -200C prior to electrophoresis and lyophilized. The radioactivity present in the samples was visualized by fluorography using Kodak X-Omat AR film and Enlightning (DuPont), and the intensity of the bands was determined by automatic integrating densitometry.
RESULTS AND DISCUSSION
Treatment of apI with Cathepsin B. Since endosomal cysteine proteinases have been implicated in the proteolytic degradation of the DR-associated I chain (10, 11), we investigated the susceptibility of highly purified DR apI to digestion with the cysteine proteinase cathepsin B. a131 was incubated with various concentrations of cathepsin B for 1 hr and the reaction products were analyzed by SDS/PAGE. Fig.  lA demonstrates that whereas the intensity of the DR13 chain (27 kDa) remained relatively constant during the incubation, there was a concentration-dependent loss of protein in the 35-kDa range (containing the DR a and I chains). Concomitant with this loss was the accumulation of proteolytic fragments of 24 kDa, 22 kDa, 15 kDa, and lower molecular mass material that migrated at the dye front.
The generation of a31 fragments by cathepsin B (50 ,.ug/ml) was next studied as a function of time. Fig. 1B demonstrates that, after as little as 0.5 hr, significant amounts of the 24-kDa and 22-kDa species had accumulated, but by 2 hr the levels of these two species had dropped dramatically. By contrast, the levels of the 15-kDa material and lower molecular mass material did not begin to increase appreciably until 1 hr, suggesting that the generation of these fragments was the result of proteolysis'of the 24-kDa and 22-kDa species.
2D PAGE of Cathepsin B-Treated apI. To determine if the lower molecular mass fragments were derived from the DR-associated I-chain, a,8I was incubated alone (Fig. 2A) or with cathepsin B at 25 ug/ml (Fig. 2B) or 50 jug/ml (Fig. 2C) for 1 hr and the reaction products were analyzed by 2D PAGE. As a control, ap8I was incubated with cathepsin B in the presence of the cysteine proteinase inhibitor E-64 (Fig.  2D) . Fig. 2 demonstrates that there was a concentrationdependent loss of intact I chain from apI after treatment with cathepsin B. By contrast, the DR a and pB chains appear relatively resistant to proteolysis by this enzyme. The species indicated by the long arrowhead has an apparent molecular mass of 24 kDa and migrates with the same mobility as the I chain fragment commonly referred to as "p25" (11, 17, 18) . There are also a number of basic fragments of 22 kDa (indicated by brackets) that probably account for the diffuse appearance of this material in SDS/PAGE. In addition to these larger fragments, there are also low molecular mass proteolysis products consisting of a group of very acidic 15-kDa fragments as well as a group of very basic 12-kDa fragments. Proteolysis also led to the production of small ethanol-insoluble polypeptides that migrated at the dye front of the gels (sl10 kDa). Whereas the intensity of the intact I chain decreased with increasing concentrations of cathepsin B, the intensity of the 24-kDa, 22-kDa, 15-kDa, 12-kDa, and lower molecular mass fragments increased under these conditions. These data, with the data shown in Fig. 1 , suggest that these lower molecular mass proteolysis products are derived from the intact I chain. Although the DR a chain appears totally resistant to cathepsin B, the p chain appears to migrate with a slightly decreased molecular mass at a more acidic position after treatment with this enzyme. This is almost certainly due to the well-established carboxyl-terminal peptidyldipeptidase activity of cathepsin B (19) a,3I was incubated with cathepsin B (50 ,ug/ml) in the presence or absence of the cathepsin B inhibitor E-64. After 4 hr of incubation, additional E-64 was added to each sample and the reaction products were separated by HPLC. Fig. 3A shows that aBI incubated with inactivated cathepsin B was eluted as a single high molecular mass peak [elution volume
Immunology: Roche [35S]Methionine-labeled aj3I complexes were incubated at 370C alone (A) or with cathepsin B at 25 pg/ml (B) or at 50 ,.g/ml (C) for 1 hr prior to the addition of the cathepsin B inhibitor E-64.
[35S]Methionine-labeled a,8I complexes were also incubated at 370C for 1 hr in the presence of cathepsin B (50 ,ug/ml) that had been pretreated (Ve), 11 ml]. The high molecular mass of aI is almost certainly related to the basic trimeric structure of the I chain (21) . Fig. 3B shows that there was a dramatic loss of this high molecular mass material after incubation of aBI with cathepsin B. This loss was accompanied by an increase in the amount of radiolabel eluting in peak II (Ve, 15 ml), peak III (18 ml), peak IV (21 ml), and peak V (25 ml).
To identify the products released by the incubation of a,8I with cathepsin B, samples of the protein present in each HPLC fraction were analyzed by SDS/PAGE and the material in each peak was pooled and analyzed by 2D PAGE. Fig. 4A and 2D PAGE (data not shown) confirm that a.BI incubated with inactivated cathepsin B was eluted as a single peak at 11 ml and contained the DR a, 3, and I chains. By contrast, Fig. 4B and Fig. 51 demonstrate that after incubation of aI with cathepsin B, the high molecular mass material in peak I contains DR a and ,B chains associated with the very basic 12-kDa I chain fragment and other small ethanol-insoluble polypeptides. Additional experiments demonstrated that any residual 24-kDa and 22-kDa I chain fragments also eluted in this peak (data not shown). Fig. 3B was pooled, precipitated with ethanol, and visualized by 2D PAGE and fluorography. The material in I-Ill correspond to peaks I-III in Fig. 3B , respectively. The positions of the DR a and , 1 chains as well as the major I chain proteolysis products at 15 kDa (solid arrow) and 12 kDa (open arrow) are indicated. Note the many small I chain-derived polypeptides (which migrate with the dye front) specifically associated with the material in peak I. appearance of these chains in peak II (Vs, 15 ml). This is the exact elution position of affinity-purified a,8 heterodimers (12, 13) . PAGE (2D) confirmed that peak II contains essentially pure DR a and 18 chains (Fig. I!) and chemical cross-linking with dithiobis(succinimidylpropionate) demonstrated that these chains were physically associated as ac1 heterodimers (data not shown). The effect of the peptidyldipeptidase activity of cathepsin B on the DR chain is readily apparent in this figure. Automatic integrating densitometry of the fluorograph demonstrated that the a and chains were present in every fraction of peaks I and II in an equimolar ratio (actual estimate = 1.1 to 1, by assuming that the DR a and ,3 chains have three and two labeled methionine residues, respectively; refs. 20 and 22) . This analysis also revealed that 56% of all a chains and 52% of all chains were present in peak II (see also Fig. 6 ). Fig. 4B and Fig. 5III shows that the material in peak III (Ve, 18 A parallel immunoblot of these fractions using the DR-specific antiserum 247HSB (13) showed an essentially identical elution profile for the DR a chain (data not shown (24) have proposed that the I chain does not inhibit peptide binding to class II molecules. In the latter study, however, the specificity of peptide binding was not addressed and the association of I chain with the class II a and ,B chains was not definitively shown. For these reasons, we believe the direct biochemical evidence suggesting that association with the I chain inhibits peptide binding to class II molecules.
The results ofthis investigation demonstrate that treatment of aBI with the cysteine proteinase cathepsin B results in the relatively specific proteolysis of the DR-associated I chain. These data thus strengthen the hypothesis that cysteine proteinases with acidic pH optima are responsible for I chain degradation in vivo and that proteolysis most likely occurs in acidic endosome-like compartments. As a consequence of I chain proteolysis, af3 dimers are released from the af3I complex, which is capable of very effectively binding immunogenic peptides. These results also support the idea that association with the I chain inhibits peptide binding to immature DR molecules, thus preserving the functional distinction between class I and class II molecules (25) . Exceptions to this generally observed dichotomy (26-28) may reflect competition of peptides for I chain binding to class II
